Company news
City Therapeutics, Inc. news in 2026
City Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease
November 10, 2026
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
November 4, 2026
City Therapeutics to Present at Upcoming November Investor Conferences
November 3, 2026
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 19, 2026